Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial

RCT (n=156) reports improved 5-yr recurrence free survival with metuximab: 43.4% (95% CI 33.6–55.9) in the metuximab group vs 21.7% (14.2–33.1) in the no adjuvant treatment group (HR 0.49 [0.34–0.72]; p=0.0031).

SPS commentary:

Radioactive iodine-labelled metuximab is a radiolabelled monoclonal antibody against the CD147 (also known as basigin or HAb18G) antigen that is expressed in heparocellular carcinoma.


Lancet Gastroenterology and Hepatology